FluoGuide AS
96X
Company Profile
Business description
FluoGuide AS is a late-stage clinical biotechnology company focused on precision cancer surgery. Its flagship product, FG001, is a uPAR-targeted fluorescent imaging agent designed to help visualize cancer tissue during surgical procedures. The company is developing FG001 for use across multiple cancer indications.
Contact
Titanhus, Titangade 9-13
CopenhagenDK-2200
DNKT: +45 31226660
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
SK Hynix Earnings: We raise fair value estimate on strong AI memory demand
Shares jumped 9% after earnings, as stronger AI memory prices boosted the chipmaker’s outlook.
stocks
Meta shares are down 12% since earnings. Is the stock a buy?
Concerns about equity sales to finance AI investments have pressured shares.
stocks
SpaceX earnings: We raise our fair value estimate on scaling data centres, but is the stock a buy?
AI data center revenue is growing fast, but questions about durability remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,971.40 | 2.60 | 0.03% |
| CAC 40 | 7,886.96 | 0.18 | -0.00% |
| DAX 40 | 25,704.02 | 113.25 | 0.44% |
| Dow JONES (US) | 52,475.10 | 97.53 | 0.19% |
| FTSE 100 | 10,694.50 | 7.96 | 0.07% |
| HKSE | 23,094.83 | 53.51 | 0.23% |
| NASDAQ | 26,549.85 | 72.04 | 0.27% |
| Nikkei 225 | 63,954.19 | 685.82 | 1.08% |
| NZX 50 Index | 13,694.71 | 3.38 | 0.02% |
| S&P 500 | 7,743.98 | 21.38 | 0.28% |
| S&P/ASX 200 | 8,847.30 | 2.80 | -0.03% |
| SSE Composite Index | 3,681.47 | 33.17 | 0.91% |